GLP-1

Aniket Pujari September 27, 2026

Battle for Weight-Loss Dominance: Novo Nordisk Charts Next Phase as Eli Lilly Gains Ground in GLP-1 Race

Novo Nordisk is navigating a pivotal phase in the weight-loss market as competitor Eli Lilly gains market share with Zepbound. Explore how both pharmaceutical leaders…

Business

Aniket Pujari September 23, 2026

Medicare GLP-1 Surge: 700,000 Seniors Start Therapy as Eli Lilly Captures 70% Market Share

Medicare’s expanded coverage has driven 700,000 seniors to start GLP-1 medications since July, with Eli Lilly securing a massive 70% share of new prescriptions, according…

Business

Aniket Pujari September 22, 2026

Eli Lilly Ramps Up Foundayo Production to Meet Surging Demand for Oral GLP-1 Weight-Loss Pills

Eli Lilly is expanding manufacturing for its oral weight-loss drug Foundayo after CEO David Ricks revealed one-third of new GLP-1 pill patients are choosing the…

Business

Aniket Pujari September 14, 2026

Novo Rebrands and Refines Global Strategy as Race for Obesity Market Dominance Escalates

Novo Nordisk unveils a major corporate rebranding to Novo as CEO Mike Doustdar outlines a revised obesity strategy to address rising competition from Eli Lilly.

Battle for Weight-Loss Dominance: Novo Nordisk Charts Next Phase as Eli Lilly Gains Ground in GLP-1 Race

Medicare GLP-1 Surge: 700,000 Seniors Start Therapy as Eli Lilly Captures 70% Market Share

Eli Lilly Ramps Up Foundayo Production to Meet Surging Demand for Oral GLP-1 Weight-Loss Pills

Novo Rebrands and Refines Global Strategy as Race for Obesity Market Dominance Escalates

You Missed

Feline Economy Flourishes: How Rising Cat Ownership and Premium Spending Are Reshaping Pet Retail

Severed Verizon Fiber Cable Causes Massive Air Traffic Delays Across East Coast Airports

McDonald’s Investor Day: 4 Key Priorities as the Fast-Food Giant Navigates U.S. Sales Headwinds

McDonald’s Shares Dip as Fast-Food Giant Outlines Costly ‘NEXT’ Growth Strategy